Eli Lilly misses estimates for top-selling diabetes drug Trulicity, shares slip

Eli Lilly and Co reported lower-than-expected sales for its top-selling diabetes drug Trulicity on Tuesday and said it expects further hits from price declines in the United States, sending its shares down 3 percent.